Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

This study is being done to find out how effective Low Level Laser Therapy (LLLT - Erchonia®
Zerona™ 2.0 Laser) is compared to Lorcaserin (Belviq®) in helping overweight people reduce
their weight gain - especially in the central body region. Subjects will undergo 2 screening
visits in which the investigators will take their medical and weight concern histories; and
if found eligible, they will be randomized to one of three groups: 1) 12 weeks of LLLT, 2)
12 weeks of Lorcaserin, and 3) 12 weeks of a combination of both Lorcaserin and LLLT. Full
study participation will last approximately 6 months and consists of 10 visits- 9 clinical
and 1 phone call. During this study subjects will be provided with weight prevention
counseling and be asked to complete 3 additional fasting blood draws. There will be one
urine pregnancy test (for females only) at the beginning of the study.

Inclusion Criteria:

- be 18-70 years of age;

- have a body weight of greater than 50 kg (110 pounds);

- have a BMI 27-39.9 kg/m2;

- be weight concerned;

- be motivated to reduce their central adiposity;

- be able to participate fully in all aspects of the study;

- have understood and signed study informed consent.

Exclusion Criteria:

- have used weight loss medications or participated in a weight loss program within the
past 30 days;

- are currently taking supplements known to affect weight, such as garcinia cambrogia.

- have had weight fluctuations of 20 pounds or more in the past 6 months (self-report);

- have an implanted device (including pacemaker or lap band) in the targeted area of
LLLT;

- have an active untreated clinically significant psychiatric condition (psychosis,
bipolar disorder, or depression);

- have used an investigational drug within 30 days of study enrollment;

- have a recent history (past 30 days) of alcohol or drug abuse or dependence;

- are currently pregnant or lactating, or are of child-bearing potential or are likely
to become pregnant during the medication phase and are unwilling to use a reliable
form of contraception;

- have a history of any major cardiovascular events including heart valve disease,
cardiac arrhythmias, congestive heart failure, acute coronary syndrome, stroke,
transient ischemic attack, or peripheral vascular disease;

- have current uncontrolled hypertension (systolic > 165 mm Hg or diastolic > 95 mm Hg)
documented on 2 separate occasions;

- have clinically significant acute or chronic progressive or unstable neurologic,
hepatic, renal, cardiovascular, lymphatic, respiratory, or metabolic disease (such as
diabetes) or active cancer or are within 1 year of cancer remission;

- Prior surgical intervention for body sculpting/weight loss, such as liposuction,
abdominoplasty, stomach stapling, lap band surgery, etc.;

- medical, physical, or other contraindications for body sculpting/weight loss;

- current use of medication(s) known to affect weight levels/cause bloating or swelling
and for which abstinence during the course of study participation is not safe or
medically prudent;

- concurrently taking a serotonergic drug (selective serotonin reuptake inhibitors
(SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase
inhibitors (MAOIs), triptans, bupropion, dextromethorphan, St. John's Wort). These
drugs can be used to treat depression and/or migraines but are contraindicated with
lorcaserin;

- any medical condition known to affect weight levels and/or to cause bloating or
swelling;

- diagnosis of, and/or taking medication for, irritable bowel syndrome;

- active infection, wound or other external trauma to the areas to be treated with the
laser;

- known photosensitivity disorder;

- are allergic to lorcaserin;

- current active cancer or currently receiving treatment for cancer; or

- have a known history of any condition or factor judged by the investigator to
preclude participation in the study or which might hinder adherence;